These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 7532487)

  • 1. [Production of monoclonal antibodies to the human respiratory syncytial virus].
    Samolovich MP; Sukhubaevskaia LP; Klimovich VB; Sominina AA
    Vestn Ross Akad Med Nauk; 1994; (9):18-21. PubMed ID: 7532487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and characterization of monoclonal antibodies directed against five structural components of human respiratory syncytial virus subgroup B.
    Orvell C; Norrby E; Mufson MA
    J Gen Virol; 1987 Dec; 68 ( Pt 12)():3125-35. PubMed ID: 2447224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation and epitope mapping of a sub-group cross-reactive anti-respiratory syncytial virus G glycoprotein monoclonal antibody which is protective in vivo.
    Robinson MJ; Tan CS; Fenwick F; Chambers CJ; Routledge EG; Toms GL
    J Med Virol; 2014 Jul; 86(7):1267-77. PubMed ID: 24415460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal Antibodies Against the Human Respiratory Syncytial Virus Obtained by Immunization with Epitope Peptides and CpG-DNA-liposome Complex.
    Park BK; Choi SH; Kim YE; Park S; Lee Y; Lee KW; Kwon HJ
    Monoclon Antib Immunodiagn Immunother; 2015 Apr; 34(2):101-9. PubMed ID: 25897608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the binding of monoclonal and polyclonal antibodies to the glycoproteins of antigenic variants of human respiratory syncytial virus by surface plasmon resonance.
    McGill A; Marsh R; Craft AW; Toms GL
    J Immunol Methods; 2005 Feb; 297(1-2):143-52. PubMed ID: 15777938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the antibody specificities of human convalescent-phase sera against the attachment (G) protein of human respiratory syncytial virus: influence of strain variation and carbohydrate side chains.
    Palomo C; Cane PA; Melero JA
    J Med Virol; 2000 Apr; 60(4):468-74. PubMed ID: 10686032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease.
    Spender LC; Hussell T; Openshaw PJ
    J Gen Virol; 1998 Jul; 79 ( Pt 7)():1751-8. PubMed ID: 9680139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Human Monoclonal Antibodies Against Respiratory Syncytial Virus Using a High Efficiency Human Hybridoma Technique.
    Alvarado G; Crowe JE
    Methods Mol Biol; 2016; 1442():63-76. PubMed ID: 27464688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hybridoma cell lines secreting monoclonal antibodies to foot-and-mouth disease virus type Asia-1.
    Butchaiah G; Rao BU
    Acta Virol; 1989 Mar; 33(2):121-30. PubMed ID: 2569807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The induction of respiratory syncytial virus-specific cytotoxic T-cell responses following immunization with a synthetic peptide containing a fusion peptide linked to a cytotoxic T lymphocyte epitope.
    Hsu SC; Shaw DM; Steward MW
    Immunology; 1995 Jul; 85(3):347-50. PubMed ID: 7558120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigenic and polypeptide structure of turkey enteric coronaviruses as defined by monoclonal antibodies.
    Dea S; Tijssen P
    J Gen Virol; 1989 Jul; 70 ( Pt 7)():1725-41. PubMed ID: 2472464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein.
    Martínez I; Melero JA
    J Gen Virol; 1998 Sep; 79 ( Pt 9)():2215-20. PubMed ID: 9747731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production and characterization of monoclonal antibodies to bovine respiratory syncytial virus.
    Underwood WJ; McCallum Q; Velicer LF; Mufson MA; Baker JC
    Vet Microbiol; 1995 Feb; 43(2-3):261-74. PubMed ID: 7740764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients.
    Collarini EJ; Lee FE; Foord O; Park M; Sperinde G; Wu H; Harriman WD; Carroll SF; Ellsworth SL; Anderson LJ; Tripp RA; Walsh EE; Keyt BA; Kauvar LM
    J Immunol; 2009 Nov; 183(10):6338-45. PubMed ID: 19841167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities.
    Sastre P; Melero JA; García-Barreno B; Palomo C
    Vaccine; 2004 Dec; 23(4):435-43. PubMed ID: 15530691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens.
    Shahhosseini S; Das D; Qiu X; Feldmann H; Jones SM; Suresh MR
    J Virol Methods; 2007 Jul; 143(1):29-37. PubMed ID: 17368819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Porcine reproductive and respiratory syndrome virus (PRRSV)-specific mAbs: supporting diagnostics and providing new insights into the antigenic properties of the virus.
    Van Breedam W; Costers S; Vanhee M; Gagnon CA; Rodríguez-Gómez IM; Geldhof M; Verbeeck M; Van Doorsselaere J; Karniychuk U; Nauwynck HJ
    Vet Immunol Immunopathol; 2011 Jun; 141(3-4):246-57. PubMed ID: 21470695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and characterization of hybridomas secreting monoclonal antibodies to tick-borne encephalitis virus.
    Kushch AA; Novák M; Melnikova YeE ; Gaidamovich SYa ; Gresíková M; Sekeyová M; Novokhatsky AS; Mikheeva TG; Sveshnikova NA; Borecký L
    Acta Virol; 1986 May; 30(3):199-205. PubMed ID: 2874723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge.
    Fisher RG; Johnson JE; Dillon SB; Parker RA; Graham BS
    J Infect Dis; 1999 Sep; 180(3):708-13. PubMed ID: 10438358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human respiratory syncytial virus vaccine antigen produced in plants.
    Belanger H; Fleysh N; Cox S; Bartman G; Deka D; Trudel M; Koprowski H; Yusibov V
    FASEB J; 2000 Nov; 14(14):2323-8. PubMed ID: 11053254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.